China Biotech in Review: U.S. Charges 4 China API Makers With Price-Fixing

chinabiotodaynewlogo ChinaBio Today submits:

Four China API companies have been charged with price fixing in a U.S. antitrust case (see here). According to the plaintiffs, the four companies, representing about 60% of the worlds vitamin C production, signed a document in 2001 limiting the amount of vitamin C each one could export. The defendants are not contesting the facts, choosing instead to raise an unusual defense: The government of China mandated the collusion.

China credited increased surveillance for rapid identification of a new pathogen that caused death in 30% of all diagnosed cases (see here). In 2009 and 2010, at least 240 cases of severe fever with thrombocytopenia syndrome (SFTS) occurred in rural sections of eastern China. China scientists, working with a grant from the China Mega-Project for Infectious Diseases, identified a tick as the carrier. The researchers did not find evidence of human-to-human transmission.

Transactions

Jilin Jian Yisheng Pharma, a TCM drugmaker, completed


Complete Story

Comments

Popular posts from this blog

*What's Happening*

- Starbucks Menu Expands in China

*What's Happening*


- Kingway Parent Intervenes in

*What's Happening *

- Starbucks to take on Nestle in